Lexaria is Now expanding its revenue Stream. $L
Post# of 103026
(Total Views: 191)
Posted On: 10/04/2020 11:06:55 AM
Lexaria is Now expanding its revenue Stream.
$LXRP. The company has licensed DehydraTECH™ to multiple companies across different sectors, including Altria, where the goal would be to develop smokeless, oral-based nicotine products. Other licensees include companies that produce cannabinoid beverages, edibles, and oral products. To quickly capitalize on market opportunities, Lexaria operates a licensed in-house research laboratory and owns a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.
New Deals, Ongoing Studies Set Stage For Strong Finish In 2020
The stage is set to produce at least one near term catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year. However, late-breaking news, similar to the British American Tobacco agreement, can come at any time. And as the value of its DehydraTECH™ platform becomes more mainstream, those events are likely to occur.
Moreover, Lexaria is already leveraging established relationships with multiple pharmaceutical, nicotine, and cannabis/CBD companies to create more effective treatments and revenue-generating opportunities. And while the BTI agreement may be one of the new partnerships, the company has stated on occasion that they are in discussions with large tobacco companies to secure additional working relationships by the end of this year. That's a plurality of opportunity.
Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020. For Lexaria, and its investors, combining the sum of the parts may equate to a great opportunity, especially at current price levels.
While no investment is without risk, Lexaria has come a long way to mitigate its downside by securing important agreements and contracts with some of the world's largest companies. Having deep-pocketed allies is always welcome.
Along with a robust and innovative drug delivery platform, those relationships may play an important factor in positioning Lexaria for near and long-term success.
https://www.marketwatch.com/press-release/lex...2020-09-14
$LXRP. The company has licensed DehydraTECH™ to multiple companies across different sectors, including Altria, where the goal would be to develop smokeless, oral-based nicotine products. Other licensees include companies that produce cannabinoid beverages, edibles, and oral products. To quickly capitalize on market opportunities, Lexaria operates a licensed in-house research laboratory and owns a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.
New Deals, Ongoing Studies Set Stage For Strong Finish In 2020
The stage is set to produce at least one near term catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year. However, late-breaking news, similar to the British American Tobacco agreement, can come at any time. And as the value of its DehydraTECH™ platform becomes more mainstream, those events are likely to occur.
Moreover, Lexaria is already leveraging established relationships with multiple pharmaceutical, nicotine, and cannabis/CBD companies to create more effective treatments and revenue-generating opportunities. And while the BTI agreement may be one of the new partnerships, the company has stated on occasion that they are in discussions with large tobacco companies to secure additional working relationships by the end of this year. That's a plurality of opportunity.
Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020. For Lexaria, and its investors, combining the sum of the parts may equate to a great opportunity, especially at current price levels.
While no investment is without risk, Lexaria has come a long way to mitigate its downside by securing important agreements and contracts with some of the world's largest companies. Having deep-pocketed allies is always welcome.
Along with a robust and innovative drug delivery platform, those relationships may play an important factor in positioning Lexaria for near and long-term success.
https://www.marketwatch.com/press-release/lex...2020-09-14
(0)
(0)
Robert
Scroll down for more posts ▼